Science Explorer Interactive view Map
Company · Seoul · South Korea

Daiichi-Sankyo (South Korea)

Research works
55
▼ 5% vs 2013–17
Citations
845
15.4 per fractional work
Top-10% rate
8.2%
record average 16.5%
Open access
54%
world 28%

Not ranked overall: Daiichi-Sankyo (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.26× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 1.06× its world share, 1 worksBiochemistry, Geneti…Immunology and Microbiology: 1.77× its world share, 0 worksImmunology and Micro…Neuroscience: 1.73× its world share, 0 worksNeuroscienceChemistry: 1.19× its world share, 0 worksChemistryComputer Science: 0.03× its world share, 0 worksComputer ScienceEngineering: 0.15× its world share, 0 worksEngineeringMathematics: 2.13× its world share, 0 worksMathematicsPhysics and Astronomy: 0.84× its world share, 0 worksPhysics and AstronomyHealth Professions: 0.47× its world share, 0 worksHealth ProfessionsMedicine: 3.51× its world share, 12 worksMedicineNursing: 0.71× its world share, 0 worksNursingDecision Sciences: 0.97× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 3.85× its world share, 2 worksEconomics, Econometr…Psychology: 0.31× its world share, 0 worksPsychologySocial Sciences: 0.06× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Economics, Econometrics and Finance, 3.9×. Every wedge is a field page.

Which keywords describe research at Daiichi-Sankyo (South Korea)?

By fractional works in all years, weighted toward what it does more of than the world: Guidelines, Anticoagulant Therapy, Quality of Life, Catheter Ablation, Stroke Prevention, Atrial Fibrillation, Risk Stratification and Thromboembolism.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Guidelines4▲ 17×6 topics
  2. Quality of Life4▲ 6.0×8 topics
  3. Anticoagulant Therapy4▲ 65×3 topics
  4. Catheter Ablation4▲ 57×2 topics
  5. Atrial Fibrillation4▲ 70×2 topics
  6. Stroke Prevention4▲ 54×2 topics
  7. Risk Stratification4▲ 99×1 topic
  8. Thromboembolism4▲ 99×1 topic
  9. Cost-effectiveness Analysis3▲ 78×1 topic
  10. Health Utility Measures3▲ 78×1 topic
  11. Inflammation3▲ 2.4×27 topics
  12. Risk Factors3▲ 5.3×8 topics
  13. Clinical Trials3▲ 8.1×7 topics
  14. Cardiovascular Disease3▲ 4.4×12 topics
  15. Clinical Practice Guidelines3▲ 8.7×11 topics
  16. Cardiovascular Events3▲ 29×4 topics
  17. Chemotherapy2▲ 6.5×14 topics
  18. Cancer2▲ 2.8×15 topics
  19. Breast Cancer2▲ 11×6 topics
  20. Cardiovascular Disease Prevention2▲ 39×2 topics
  21. Global Burden2▲ 5.8×3 topics
  22. Percutaneous Coronary Intervention2▲ 20×3 topics
  23. Genetic Polymorphisms2▲ 36×2 topics
  24. Genetic Variants2▲ 13×3 topics
  25. Antithrombotic Therapy2▲ 26×2 topics
  26. Aspirin2▲ 98×1 topic
  27. C-Reactive Protein2▲ 32×2 topics
  28. Clopidogrel2▲ 98×1 topic
  29. Metabolism2▲ 4.1×8 topics
  30. Targeted Therapy2▲ 12×4 topics
  31. Cholesterol-lowering1▲ 50×1 topic
  32. LDL Cholesterol1▲ 61×1 topic
  33. Radiotherapy1▲ 6.8×6 topics
  34. Statins1▲ 31×2 topics
  35. Clinical Guidelines1▲ 7.9×4 topics
  36. Hypertension1▲ 6.6×5 topics
  37. Atherosclerosis1▲ 6.2×6 topics
  38. Diabetes Mellitus1▲ 8.9×2 topics
  39. Prophylaxis1▲ 15×2 topics
  40. Trastuzumab1▲ 46×2 topics

Which research topics does Daiichi-Sankyo (South Korea) publish most on?

By volume in 2022–2025: Atrial Fibrillation Management and Outcomes, Lipoproteins and Cardiovascular Health, Health Systems, Economic Evaluations, Quality of Life and HER2/EGFR in Cancer Research.

  1. 1 Atrial Fibrillation Management and Outcomes Cardiology and Cardiovascular Medicine 2 works
  2. 2 Lipoproteins and Cardiovascular Health Surgery 1 works
  3. 3 Health Systems, Economic Evaluations, Quality of Life Economics and Econometrics 1 works
  4. 4 HER2/EGFR in Cancer Research Oncology 1 works
  5. 5 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 0 works
  6. 6 Antiplatelet Therapy and Cardiovascular Diseases Cardiology and Cardiovascular Medicine 0 works
  7. 7 Cancer Treatment and Pharmacology Oncology 0 works
  8. 8 Musculoskeletal synovial abnormalities and treatments Rheumatology 0 works
  9. 9 Diabetes, Cardiovascular Risks, and Lipoproteins Endocrinology, Diabetes and Metabolism 0 works
  10. 10 Breast Cancer Treatment Studies Cancer Research 0 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available54.2%not open45.8%

World: 28% of research is openly available.

with international co-authors77.9%domestic only22.1%

World: 19% is written across borders.

How has Daiichi-Sankyo (South Korea)'s research output changed?

Output in 2018–2022 was 5% lower than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Seoul

All research institutions in Seoul

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.